Just now, the National Organization for Joint Procurement of Medicines issued an announcement,Some companies have filed appeals regarding the proposed winning bid price for fulvestrant injections. The proposed winning bid results for fulvestrant injections are now being re-posted.。According to publicly available data, fulvestrant injection is used for the treatment of locally advanced or metastatic breast cancer that is estrogen receptor-positive in postmenopausal women (including natural and artificial menopause) with recurrence after or during adjuvant anti-estrogen therapy, or with progression during anti-estrogen therapy.In this ninth batch of national procurement in China, the Fulvestrant Injection has been tentatively awarded to six companies: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Shandong New Time Pharmaceutical Co., Ltd., Qilu Pharmaceutical Co., Ltd., Hangzhou Jiuyuan Gene Engineering Co., Ltd., and Sichuan Huiyu Pharmaceutical Co., Ltd.。The prices announced again have increased compared to before.The previously announced proposed winning bid price for fulvestrant injection
Re-disclosed Proposed Winning Bid Price for Fulvestrant Injection
Original announcement as follows:
From November 7 to November 9, 2023, the National Joint Procurement Office for Medicines disclosed the tentative winning results of the national centralized medicine procurement (GY-YD2023-2). During the disclosure period, some companies raised appeals regarding the tentative winning price of fulvestrant injections. After careful consideration, the tentative winning results of fulvestrant injections are now being disclosed again. For details, see the attachment.If there are any objections during the publicity period, please file an appeal with the Joint Procurement Office before the end of the publicity period and provide legally valid evidence materials. Appeals will not be accepted after the deadline. In principle, the Joint Procurement Office will not accept appeals without corresponding evidence materials.Publicity Period: November 13, 2023 to November 15, 2023Acceptance Period: November 13, 2023 to November 15, 2023(Weekdays: 8:30 AM ~ 11:00 AM, 1:30 PM ~ 4:00 PM)Address: Service Department, 1st Floor, No. 622 Jumen Road, Huangpu District, ShanghaiPhone: 021-31773244; 021-31773255; 021-31773266Attachment: Proposed Winning Results Table for Fulvestrant Injection in China's Centralized Drug Procurement (GY-YD2023-2)National Organization for Joint Procurement of Medicines
